PMID- 15298047
OWN - NLM
STAT- MEDLINE
DCOM- 20041108
LR  - 20220321
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 27
IP  - 7
DP  - 2004 Jul
TI  - Association between paraoxonase-1 activity and lipid peroxidation indicator 
      levels in people living in the Antalya region with angiographically documented 
      coronary artery disease.
PG  - 426-30
AB  - BACKGROUND: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated 
      enzyme capable of hydrolyzing lipid peroxides. Thus, PON1 plays a preventing role 
      in atherosclerosis by protecting against lipid peroxidation. HYPOTHESIS: The 
      incidence of coronary artery disease (CAD) is high in the Turkish population, and 
      many risk factors have been studied as determinants of CAD. In Turkish people 
      living in the Antalya region, we aimed to determine serum PON1 activity and its 
      relation to lipoproteins and lipid peroxidation markers. METHODS: We measured the 
      activity of serum PON1 together with concentrations of a variety of lipid 
      constituents--total cholesterol (TC), low-density lipoprotein cholesterol 
      (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), HDL cholesterol 
      (HDL-C), triglycerides (TG), apolipoprotein (apo) A-I, apoB, and lipid 
      peroxidation indicators (conjugated diene [CD] and thiobarbituric acid-reactive 
      substances [TBARS])--in 108 patients with CAD and 64 healthy subjects (controls). 
      RESULTS: We found that the PON1 activity was significantly reduced in patients 
      with CAD (222.37 +/- 11.31 IU/l) compared with controls (331.75 +/- 20.98 IU/l). 
      These patients had significantly lower HDL-C, PON1/HDL-C, apoA-I, PON1/ApoA-I, 
      and ApoA-I/ApoB, and higher LDL-C, TC/HDL-C, LDL-C/HDL-C, apoB, CD and TBARS than 
      did controls. Total cholesterol and apoA-I concentrations were significantly 
      higher in women than in men in both groups. After multiple logistic regression 
      analysis, TBARS (odds ratio [OR] 568.87; p = 0.000), age (OR 1.10; p = 0.000), 
      gender (OR 4.58; p = 0.008), apoA-I/apoB (OR 0.046; p = 0.003), and PON1/apoA-I 
      (OR 0.58; p = 0.007) were independently indicative of the presence of CAD. 
      CONCLUSIONS: This is the first report of decreased serum PON1 activity and 
      increased lipid peroxidation indicators (CD and TBARS) of patients with CAD 
      living in Antalya, Turkey. Our results indicate that TBARS levels, age, gender, 
      apoA-1/ApoB, and PON1/apoA-I ratios are important markers of CAD.
FAU - Gocmen, Ayse Yesim
AU  - Gocmen AY
AD  - Department of Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, 
      Turkey.
FAU - Gumuslu, Saadet
AU  - Gumuslu S
FAU - Semiz, Ender
AU  - Semiz E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Cholesterol, VLDL)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 0 (Triglycerides)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apolipoprotein A-I/metabolism
MH  - Apolipoproteins B/metabolism
MH  - Aryldialkylphosphatase/*metabolism
MH  - Biomarkers/blood
MH  - Cholesterol, HDL/metabolism
MH  - Cholesterol, LDL/metabolism
MH  - Cholesterol, VLDL/metabolism
MH  - *Coronary Angiography
MH  - Coronary Artery Disease/diagnostic imaging/*metabolism/*physiopathology
MH  - Female
MH  - Humans
MH  - Lipid Peroxidation/*physiology
MH  - Male
MH  - Middle Aged
MH  - Statistics as Topic
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Triglycerides/metabolism
MH  - Turkey/epidemiology
PMC - PMC6654200
EDAT- 2004/08/10 05:00
MHDA- 2004/11/09 09:00
PMCR- 2006/12/05
CRDT- 2004/08/10 05:00
PHST- 2004/08/10 05:00 [pubmed]
PHST- 2004/11/09 09:00 [medline]
PHST- 2004/08/10 05:00 [entrez]
PHST- 2006/12/05 00:00 [pmc-release]
AID - CLC4960270714 [pii]
AID - 10.1002/clc.4960270714 [doi]
PST - ppublish
SO  - Clin Cardiol. 2004 Jul;27(7):426-30. doi: 10.1002/clc.4960270714.